BioXcel TherapeuticsBTAI
BTAI
About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Employees: 37
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
69% more capital invested
Capital invested by funds: $1.89M [Q3] → $3.21M (+$1.31M) [Q4]
9.65% more ownership
Funds ownership: 7.62% [Q3] → 17.27% (+9.65%) [Q4]
4% less funds holding
Funds holding: 50 [Q3] → 48 (-2) [Q4]
18% less call options, than puts
Call options by funds: $23K | Put options by funds: $28K
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$48
2,659%
upside
Avg. target
$57
3,147%
upside
High target
$65
3,636%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Rodman & Renshaw Elemer Piros 8% 1-year accuracy 1 / 12 met price target | 3,636%upside $65 | Buy Initiated | 19 Mar 2025 |
HC Wainwright & Co. Raghuram Selvaraju 30% 1-year accuracy 99 / 335 met price target | 2,659%upside $48 | Buy Maintained | 30 Jan 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
3 weeks ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI ® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2024.
Positive
Zacks Investment Research
1 month ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI ® in the home setting
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data to support potential sNDA submission for label expansion of IGALMI ® in the home setting
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,000,000 shares of Common Stock at a combined offering price of $3.50 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant, for gross proceeds of approximately $14 million before deducting the placement agent's fees and other offering expenses (excluding the proceeds, if any, from the exercise of the Accompanying Warrants). The Accompanying Warrants have an exercise price of $4.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance. The Company also granted the purchaser the option, exercisable at any time and from time to time, for two weeks after the closing of this offering to purchase up to an additional 4,000,000 Shares (or common stock equivalents in lieu thereof) and Accompanying Warrants to purchase an additional 4,000,000 shares of Common Stock from the Company, at a combined offering price of $3.50 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant.
Negative
Zacks Investment Research
1 month ago
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale in a registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,000,000 shares of Common Stock at a combined offering price of $3.50 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant, for aggregate gross proceeds to the Company of approximately $14 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company (excluding the proceeds, if any, from the exercise of the Accompanying Warrants). The Accompanying Warrants have an exercise price of $4.20 per share of Common Stock, are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire five years from the date of issuance. The Company has also granted the purchasers the option, exercisable at any time and from time to time, for two weeks after the closing of this offering to purchase up to an additional 4,000,000 Shares (or common stock equivalents in lieu thereof) and Accompanying Warrants to purchase an additional 4,000,000 shares of Common Stock from the Company, at a combined offering price of $3.50 per Share (or per common stock equivalent in leu thereof) and Accompanying Warrant.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia
FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial is closed under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Charts implemented using Lightweight Charts™